Biomerica’s inFoods® IBS test is now available at Gastro Health, providing a revolutionary new treatment for patients suffering from Irritable Bowel Syndrome (IBS).
17 avr. 2023 07h47 HE
|
Biomerica, Inc.
Gastro Health is a leading gastroenterology group with over 380 GI physicians in the United StatesClinical study results show patients who eliminated foods as determined by the inFoods® IBS test...
Biomerica announces the Launch of InFoods IBS as a Laboratory Developed Test (LDT); First patient samples have been processed
08 mars 2023 08h19 HE
|
Biomerica, Inc.
InFoods® IBS LDT validation testing at the CLIA Lab is completed and the product is now being offered commerciallyClinical trial data shows InFoods® IBS treatment diet significantly improved several...
Irritable Bowel Syndrome Pipeline Booms as 24+ Therapies Likely to Enter in the Treatment Domain | DelveInsight
18 janv. 2023 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Irritable Bowel Syndrome Pipeline Booms as 24+ Therapies Likely to Enter in the Treatment Domain | DelveInsight Irritable bowel syndrome (IBS) is a...
Biomerica Appoints Mayo Clinic Gastroenterologist, Dr. Brian E. Lacy, to the Company’s Scientific Advisory Board
10 janv. 2023 08h19 HE
|
Biomerica, Inc.
Dr. Lacy is the former co-Editor in Chief of the American Journal of Gastroenterology, the former Editor in Chief of Clinical and Translational Gastroenterology, and has served as the co-Chairman for...
Constipation Treatment Market is expected to generate a revenue of USD 29.04 Billion by 2028, Globally, at 6.77% CAGR: Verified Market Research®
13 déc. 2022 11h30 HE
|
Verified Market Research
Jersey City, New Jersey, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Verified Market Research® recently published a report, “Constipation Treatment Market” By Disease Type (Chronic idiopathic constipation...
Global Gastrointestinal Partnering Report and Directory 2022: Trends by Year, Deal Type, Stage of Development, Technology Type and Therapeutic Indication
02 déc. 2022 08h09 HE
|
Research and Markets
Dublin, Dec. 02, 2022 (GLOBE NEWSWIRE) -- The "Global Gastrointestinal Partnering 2015-2022: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering. The...
Biomerica InFoods® IBS Data Presented at the 2022 American College of Gastroenterology (ACG) Annual Scientific Meeting
02 nov. 2022 08h19 HE
|
Biomerica, Inc.
ACG Presidential Award Received for the InFoods® IBS Data Presented at the American College of Gastroenterology (ACG) Annual Scientific MeetingThe Presented Clinical Study Data Showed InFoods® IBS...
Irritable Bowel Syndrome Treatment Market Size is expected to reach at USD 4.7 Billion by 2030, registering a CAGR of 9.5%, Owing to Increasing Incidences of Gastrointestinal Disorders
03 oct. 2022 09h48 HE
|
Acumen Research and Consulting
LOS ANGELES, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Global Irritable Bowel Syndrome Treatment Market Size accounted for USD 2.1 Billion in 2021 and is projected to achieve a market size of USD 4.7...
metaMe Health partners with Launchit Ventures to market Regulora, an FDA-cleared Prescription Digital Therapeutic for adults with IBS, in Canada
29 sept. 2022 09h00 HE
|
metaMe Health, Inc.
HAMILTON, Ontario and CHICAGO, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Launchit Ventures, Inc., a HealthTech solutions provider and global commercialization partner developing new technology-led business...
Biomerica Plans Launch of InFoods® IBS Test; Names Robert Carlson as Chief Commercial Officer
30 août 2022 08h19 HE
|
Biomerica, Inc.
InFoods® IBS commercial launch and revenues expected before the close of calendar year 2022Mr. Carlson is an accomplished and performance-driven Commercial and Corporate Strategy and Development...